It took me weeks to come to terms with the fact that there were no easy answers. I couldn't change the past or the diagnosis, so I focused on educating myself and becoming Tinslee's biggest advocate. We underwent all the necessary tests, scans, and procedures, and spent a year going in for lab work and check-ups.
Directory
Kevin Haworth
Post-Doctoral Research Fellow | PhD
Dr. Haworth is a post-doctoral fellow in the Kiem Lab in Seattle. The Kiem Lab studies cell and gene therapy with a particular interested in the biology of blood and marrow stem cells and the development and use of novel genome editing technologies. The overall goal is to develop better stem cell transplant and cell and gene therapy treatments for patients with genetic and infectious diseases and cancer.
Recent studies from the Kiem lab have examined the role of endothelial cells in iPSC-derived HSC specification and expansion. We have also used endothelial cell support to expand adult marrow HSCs and used novel small molecules for expansion. We have demonstrated successful ex vivo expansion of human cord blood cells when cultured in the presence of specific small molecules. We also have 4 active clinical gene therapy studies. One study aims at treating patients with glioblastoma and we have now treated 7 patients and have shown in our most recent manuscript improved survival in high-risk patients with glioblastoma. One clinical study involves the correction of the genetic defect in blood and marrow stem cells from patients with Fanconi anemia and we have now treated 2 patients. Two clinical studies involve gene therapy approaches for patients with HIV and lymphoma undergoing either primary chemotherapy or requiring an autologous HSC transplantation. The Kiem lab is also part of multiple collaborations to improve the efficiency by which HSCs can be cultured and transduced, while closely monitoring the gene modified clones through cutting-edge high-throughput retroviral integration site analysis.
FA Research Projects
The Latest
News & Events
The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.
On May 24th, 2024, the FA Europe Network hosted its inaugural pan-European scientific meeting at the historic Saint-Louis Hospital in Paris, marking a significant milestone in international collaboration for Fanconi anemia (FA).